These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 28251391)

  • 1. A multicenter, open-label, long-term safety and tolerability study of DFN-02, an intranasal spray of sumatriptan 10 mg plus permeation enhancer DDM, for the acute treatment of episodic migraine.
    Munjal S; Brand-Schieber E; Allenby K; Spierings ELH; Cady RK; Rapoport AM
    J Headache Pain; 2017 Dec; 18(1):31. PubMed ID: 28251391
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Randomized Trial Comparing the Pharmacokinetics, Safety, and Tolerability of DFN-02, an Intranasal Sumatriptan Spray Containing a Permeation Enhancer, With Intranasal and Subcutaneous Sumatriptan in Healthy Adults.
    Munjal S; Gautam A; Offman E; Brand-Schieber E; Allenby K; Fisher DM
    Headache; 2016 Oct; 56(9):1455-1465. PubMed ID: 27613076
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DFN-02 (Sumatriptan 10 mg With a Permeation Enhancer) Nasal Spray vs Placebo in the Acute Treatment of Migraine: A Double-Blind, Placebo-Controlled Study.
    Lipton RB; Munjal S; Brand-Schieber E; Rapoport AM
    Headache; 2018 May; 58(5):676-687. PubMed ID: 29878341
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of DFN-11 (sumatriptan injection, 3 mg) in adults with episodic migraine: an 8-week open-label extension study.
    Landy S; Munjal S; Brand-Schieber E; Rapoport AM
    J Headache Pain; 2018 Aug; 19(1):70. PubMed ID: 30112725
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of DFN-11 (sumatriptan injection, 3 mg) in adults with episodic migraine: a multicenter, randomized, double-blind, placebo-controlled study.
    Landy S; Munjal S; Brand-Schieber E; Rapoport AM
    J Headache Pain; 2018 Aug; 19(1):69. PubMed ID: 30112726
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DFN-02, Sumatriptan 10 mg Nasal Spray with Permeation Enhancer, for the Acute Treatment of Migraine: A Randomized, Double-Blind, Placebo-Controlled Study Assessing Functional Disability and Subject Satisfaction with Treatment.
    Lipton RB; Munjal S; Brand-Schieber E; Rapoport AM
    CNS Drugs; 2019 Apr; 33(4):375-382. PubMed ID: 30877622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early Onset of Efficacy and Consistency of Response Across Multiple Migraine Attacks From the Randomized COMPASS Study: AVP-825 Breath Powered
    Silberstein S; Winner PK; McAllister PJ; Tepper SJ; Halker R; Mahmoud RA; Siffert J
    Headache; 2017 Jun; 57(6):862-876. PubMed ID: 28497569
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized, double-blind, crossover study comparing DFN-11 injection (3 mg subcutaneous sumatriptan) with 6 mg subcutaneous sumatriptan for the treatment of rapidly-escalating attacks of episodic migraine.
    Cady RK; Munjal S; Cady RJ; Manley HR; Brand-Schieber E
    J Headache Pain; 2017 Dec; 18(1):17. PubMed ID: 28176235
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiple-attack efficacy and tolerability of sumatriptan nasal spray in the treatment of migraine.
    Diamond S; Elkind A; Jackson RT; Ryan R; DeBussey S; Asgharnejad M
    Arch Fam Med; 1998; 7(3):234-40. PubMed ID: 9596457
    [TBL] [Abstract][Full Text] [Related]  

  • 10. One-year tolerability and efficacy of sumatriptan nasal spray in adolescents with migraine: results of a multicenter, open-label study.
    Rothner AD; Winner P; Nett R; Asgharnejad M; Laurenza A; Austin R; Peykamian M
    Clin Ther; 2000 Dec; 22(12):1533-46. PubMed ID: 11192144
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term evaluation of sumatriptan and naproxen sodium for the acute treatment of migraine in adolescents.
    McDonald SA; Hershey AD; Pearlman E; Lewis D; Winner PK; Rothner D; Linder SL; Runken MC; Richard NE; Derosier FJ
    Headache; 2011 Oct; 51(9):1374-87. PubMed ID: 21797863
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An open-label trial of a sumatriptan auto-injector for migraine in patients currently treated with subcutaneous sumatriptan.
    Landy SH; Tepper SJ; Wein T; Schweizer E; Ramos E
    Headache; 2013 Jan; 53(1):118-125. PubMed ID: 23148799
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Twelve-month tolerability and safety of sumatriptan-naproxen sodium for the treatment of acute migraine.
    Winner P; Cady RK; Ruoff GE; Frishberg BM; Alexander WJ; Zhang Y; Kori SH; Lener SE
    Mayo Clin Proc; 2007 Jan; 82(1):61-8. PubMed ID: 17285787
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Sumatriptan nasal spray 20mg: efficacy, tolerance and quality of life in migraine patients].
    Géraud G; Valette C
    Rev Neurol (Paris); 2000 Jul; 156(6-7):646-53. PubMed ID: 10891800
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic Characterization and Dose Selection of a Novel Sumatriptan Nasal Spray Formulation, DFN-02.
    Pal A; Gautam A; Munjal S
    J Clin Pharmacol; 2017 Nov; 57(11):1472-1478. PubMed ID: 28597922
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AVP-825 breath-powered intranasal delivery system containing 22 mg sumatriptan powder vs 100 mg oral sumatriptan in the acute treatment of migraines (The COMPASS study): a comparative randomized clinical trial across multiple attacks.
    Tepper SJ; Cady RK; Silberstein S; Messina J; Mahmoud RA; Djupesland PG; Shin P; Siffert J
    Headache; 2015 May; 55(5):621-35. PubMed ID: 25941016
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety, tolerability, and pharmacokinetics of sumatriptan in healthy subjects following ascending single intranasal doses and multiple intranasal doses.
    Moore KH; Hussey EK; Shaw S; Fuseau E; Duquesnoy C; Pakes GE
    Cephalalgia; 1997 Jun; 17(4):541-50. PubMed ID: 9209776
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the Pharmacokinetic Interaction of Ubrogepant Coadministered With Sumatriptan and of the Safety of Ubrogepant With Triptans.
    Jakate A; Boinpally R; Butler M; Lu K; McGeeney D; Periclou A
    Headache; 2020 Jul; 60(7):1340-1350. PubMed ID: 32573795
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term tolerability of sumatriptan nasal spray in adolescent patients with migraine.
    Natarajan S; Jabbour JT; Webster CJ; Richardson MS
    Headache; 2004; 44(10):969-77. PubMed ID: 15546259
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized, double-blind, placebo-controlled study of breath powered nasal delivery of sumatriptan powder (AVP-825) in the treatment of acute migraine (The TARGET Study).
    Cady RK; McAllister PJ; Spierings EL; Messina J; Carothers J; Djupesland PG; Mahmoud RA
    Headache; 2015 Jan; 55(1):88-100. PubMed ID: 25355310
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.